Your browser doesn't support javascript.
loading
Risk of thyroid as a first or second primary cancer. A population-based study in Italy, 1998-2012.
Crocetti, Emanuele; Mattioli, Veronica; Buzzoni, Carlotta; Franceschi, Silvia; Serraino, Diego; Vaccarella, Salvatore; Ferretti, Stefano; Busco, Susanna; Fedeli, Ugo; Varvarà, Massimo; Falcini, Fabio; Zorzi, Manuel; Carrozzi, Giuliano; Mazzucco, Walter; Gasparotti, Cinzia; Iacovacci, Silvia; Toffolutti, Federica; Cavallo, Rossella; Stracci, Fabrizio; Russo, Antonio G; Caldarella, Adele; Rosso, Stefano; Musolino, Antonino; Mangone, Lucia; Casella, Claudia; Fusco, Mario; Tagliabue, Giovanna; Piras, Daniela; Tumino, Rosario; Guarda, Linda; Dinaro, Ylenia M; Piffer, Silvano; Pinna, Pasquala; Mazzoleni, Guido; Fanetti, Anna C; Dal Maso, Luigino.
Afiliação
  • Crocetti E; Cancer Epidemiology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy.
  • Mattioli V; Cancer Epidemiology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy.
  • Buzzoni C; Global Patient Outcomes and Real World Evidence (GPORWE) International Eli Lilly Italy S.p.A, Sesto Fiorentino, Florence, Italy.
  • Franceschi S; AIRTUM Database (in charge until January 2019), Florence, Italy.
  • Serraino D; Cancer Epidemiology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy.
  • Vaccarella S; Cancer Epidemiology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy.
  • Ferretti S; Section of Cancer Surveillance, International Agency for Research on Cancer, Lyon, France.
  • Busco S; Romagna Cancer Registry, Section of Ferrara, Local Health Unit, University of Ferrara, Ferrara, Italy.
  • Fedeli U; Cancer Registry of Latina Province, ASL Latina, Latina, Italy.
  • Varvarà M; Epidemiological Department, Azienda Zero, Padua, Italy.
  • Falcini F; Registro Tumori Integrato Catania-Messina-Siracusa-Enna, Università degli Studi di Catania, Catania, Italy.
  • Zorzi M; Romagna Cancer Registry, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), IRCCS, Meldola, Italy.
  • Carrozzi G; Veneto Tumor Registry, Azienda Zero, Padua, Italy.
  • Mazzucco W; Modena Cancer Registry, Public Health Department, AUSL Modena, Modena, Italy.
  • Gasparotti C; Palermo and Province Cancer Registry, Clinical Epidemiology Unit with Cancer Registry, Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone", University of Palermo, Palermo, Italy.
  • Iacovacci S; Brescia Cancer Registry, Epidemiology Unit, Brescia Health Protection Agency, Brescia, Italy.
  • Toffolutti F; Cancer Registry of Latina Province, ASL Latina, Latina, Italy.
  • Cavallo R; Cancer Epidemiology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy.
  • Stracci F; ASL Salerno Cancer Registry, Salerno, Italy.
  • Russo AG; Public Health Section, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
  • Caldarella A; Cancer Registry of Milan, Epidemiology Unit, Agency for Health Protection, Milan, Italy.
  • Rosso S; Tuscany Cancer Registry, Clinical Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Florence, Italy.
  • Musolino A; Piedmont Cancer Registry, Azienda Ospedaliera-Universitaria Città della Salute e della Scienza di Torino, Italy.
  • Mangone L; Parma Cancer Registry, Oncology Unit, Azienda Ospedaliera Universitaria di Parma, Parma, Italy.
  • Casella C; Reggio Emilia Cancer Registry, Epidemiology Unit, AUSL ASMN-IRCCS, Azienda USL di Reggio Emilia, Reggio Emilia, Italy.
  • Fusco M; Liguria Cancer Registry, Clinical Epidemiology, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
  • Tagliabue G; Cancer Registry of ASL Napoli 3 Sud, Napoli, Italy.
  • Piras D; Lombardy Cancer Registry, Cancer Registry Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Tumino R; North Sardinia Cancer Registry, Azienda Regionale per la Tutela della Salute, Sassari, Italy.
  • Guarda L; Cancer Registry and Histopathology Department, Provincial Health Authority (ASP 7), Ragusa, Italy.
  • Dinaro YM; Mantova Cancer Registry, Epidemilogy Unit, Agenzia di Tutela della Salute (ATS) della Val Padana, Mantova, Italy.
  • Piffer S; Siracusa Cancer Registry, Health Unit of Siracusa, Siracusa, Italy.
  • Pinna P; Trento Province Cancer Registry, Unit of Clinical Epidemiology, Trento, Italy.
  • Mazzoleni G; Nuoro Cancer Registry, RT Nuoro, ASSL Nuoro/ATS Sardegna, Nuoro, Italy.
  • Fanetti AC; Southtyrol Cancer Registry, Bolzano, Italy.
  • Dal Maso L; Sondrio Cancer Registry, Health Protection Agency, Sondrio, Italy.
Cancer Med ; 10(19): 6855-6867, 2021 10.
Article em En | MEDLINE | ID: mdl-34533289
ABSTRACT

BACKGROUND:

The number of patients living after a cancer diagnosis is increasing, especially after thyroid cancer (TC). This study aims at evaluating both the risk of a second primary cancer (SPC) in TC patients and the risk of TC as a SPC.

METHODS:

We analyzed two population-based cohorts of individuals with TC or other neoplasms diagnosed between 1998 and 2012, in 28 Italian areas covered by population-based cancer registries. Standardized incidence ratios (SIRs) of SPC were stratified by sex, age, and time since first cancer.

RESULTS:

A total of 38,535 TC patients and 1,329,624 patients with other primary cancers were included. The overall SIR was 1.16 (95% CI 1.12-1.21) for SPC in TC patients, though no increase was shown for people with follicular (1.06) and medullary (0.95) TC. SPC with significantly increased SIRs was bone/soft tissue (2.0), breast (1.2), prostate (1.4), kidney (2.2), and hemolymphopoietic (1.4) cancers. The overall SIR for TC as a SPC was 1.49 (95% CI 1.42-1.55), similar for all TC subtypes, and it was significantly increased for people diagnosed with head and neck (2.1), colon-rectum (1.4), lung (1.8), melanoma (2.0), bone/soft tissue (2.8), breast (1.3), corpus uteri (1.4), prostate (1.5), kidney (3.2), central nervous system (2.3), and hemolymphopoietic (1.8) cancers.

CONCLUSIONS:

The increased risk of TC after many other neoplasms and of few SPC after TC questions the best way to follow-up cancer patients, avoiding overdiagnosis and overtreatment for TC and, possibly, for other malignancies.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Glândula Tireoide / Segunda Neoplasia Primária Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male País/Região como assunto: Europa Idioma: En Revista: Cancer Med Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Itália

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Glândula Tireoide / Segunda Neoplasia Primária Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male País/Região como assunto: Europa Idioma: En Revista: Cancer Med Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Itália